- H.C. Wainwright initiates coverage of PhamAthene (PIP) with a Buy rating and $4 price target.
- Bullish outlook based mainly on a successful outcome of its litigation with SIGA Technologies over the small pox antiviral product Arestvyr.
- Shares currently trade at $1.95.
- 19 mutual funds have positions, up from 15 a year earlier.
PharmAthene started at Buy
Recommended For You
About ALT Stock
Related Stocks
| Symbol | Last Price | % Chg |
|---|---|---|
| ALT | - | - |
| Altimmune, Inc. | ||